文献速递炎症性肠病消化道肿瘤与早癌肝病

原发性硬化性胆管炎合并炎症性肠病患者进展期结直肠肿瘤风险高

High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-03-15

该回顾性纵向研究纳入1911例结肠炎症性肠病(IBD)患者(293例合并原发性硬化性胆管炎(PSC),1618例不合并PSC),2000至2015年在荷兰或美国接受超过2次监测性结肠镜检查。结果显示,PSC-IBD患者发生进展期结直肠肿瘤(aCRN)的风险是非PSC IBD患者的2倍,且低级别上皮内瘤变(LGD)后aCRN发生率显著更高(8.4/100患者年 vs 3.0/100患者年,P=0.01),PSC、年龄增长和活动性炎症为独立危险因素。

要点

  • PSC-IBD患者aCRN风险为非PSC IBD的2倍。
  • LGD后aCRN发生率PSC-IBD为8.4/100患者年,非PSC IBD为3.0/100患者年(P=0.01)。
  • PSC、年龄增长和活动性炎症是aCRN独立危险因素。

核心结论

  • 在近2000例结肠IBD患者的纵向研究中,PSC仍是aCRN的强独立危险因素。
  • 一旦检测到LGD,PSC患者aCRN发生率更高,且病变更常为内镜下不可见。
  • 研究结果支持对IBD合并PSC患者进行仔细的年度结肠镜监测,并在检测到LGD时考虑结肠切除术。

研究设计与样本

  • 回顾性纵向研究,纳入1911例结肠IBD患者(293例合并PSC,1618例不合并PSC),2000至2015年在荷兰或美国接受超过2次监测性结肠镜检查,共9265患者年随访。

主要发现

  • PSC-IBD患者发生aCRN的风险为非PSC IBD患者的2倍。
  • PSC-IBD患者平均炎症评分0.55 vs 非PSC IBD患者0.56,差异无统计学意义(P=0.89)。
  • PSC-IBD患者LGD比例为21% vs 非PSC IBD患者18%,差异无统计学意义(P=0.37)。
  • LGD诊断后aCRN发生率PSC-IBD患者为8.4/100患者年 vs 非PSC IBD患者3.0/100患者年(P=0.01)。
  • aCRN独立危险因素包括PSC(aHR 2.01;95%CI 1.09-3.71)、年龄增长(aHR 1.03;95%CI 1.01-1.05)和活动性炎症(aHR 2.39;95%CI 1.63-3.49)。

临床怎么用

  • 研究结果支持对IBD合并PSC患者进行仔细的年度结肠镜监测。
  • 研究结果支持在检测到LGD时考虑结肠切除术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC, termed PSC-IBD) are at increased risk for colorectal cancer, but their risk following a diagnosis of low-grade dysplasia (LGD) is not well described. We aimed to determine the rate of advanced colorectal neoplasia (aCRN), defined as high-grade dysplasia and/or colorectal cancer, following a diagnosis of indefinite dysplasia or LGD in this population. METHODS: We performed a retrospective, longitudinal study of 1911 patients with colonic IBD (293 with PSC and 1618 without PSC) who underwent more than 2 surveillance colonoscopies from 2000 through 2015 in The Netherlands or the United States (9265 patient-years of follow-up evaluation). We collected data on clinical and demographic features of patients, as well as data from each surveillance colonoscopy and histologic report. For each surveillance colonoscopy, the severity of active inflammation was documented. The primary outcome was a diagnosis of aCRN during follow-up evaluation. We also investigated factors associated with aCRN in patients with or without a prior diagnosis of indefinite dysplasia or LGD. RESULTS: Patients with PSC-IBD had a 2-fold higher risk of developing aCRN than patients with non-PSC IBD. Mean inflammation scores did not differ significantly between patients with PSC-IBD (0.55) vs patients with non-PSC IBD (0.56) (P = .89), nor did proportions of patients with LGD (21% of patients with PSC-IBD vs 18% of patients with non-PSC IBD) differ significantly (P = .37). However, the rate of aCRN following a diagnosis of LGD was significantly higher in patients with PSC-IBD (8.4 per 100 patient-years) than patients with non-PSC IBD (3.0 per 100 patient-years; P = .01). PSC (adjusted hazard ratio [aHR], 2.01; 95% CI, 1.09-3.71), increasing age (aHR 1.03; 95% CI, 1.01-1.05), and active inflammation (aHR, 2.39; 95% CI, 1.63-3.49) were independent risk factors for aCRN. Dysplasia was more often endoscopically invisible in patients with PSC-IBD than in patients with non-PSC IBD. CONCLUSIONS: In a longitudinal study of almost 2000 patients with colonic IBD, PSC remained a strong independent risk factor for aCRN. Once LGD is detected, aCRN develops at a higher rate in patients with PSC and is more often endoscopically invisible than in patients with only IBD. Our findings support recommendations for careful annual colonoscopic surveillance for patients with IBD and PSC, and consideration of colectomy once LGD is detected.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Shah SC, Ten Hove JR, Castaneda D, et al. High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018. PMID: 29378311. doi:10.1016/j.cgh.2018.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。